review of nvp and hg and early pharmacotherapeutic intervention对一步法和hg和pharmacotherapeutic早期干预.pdfVIP

Hindawi Publishing Corporation Obstetrics and Gynecology International Volume 2012, Article ID 252676, 8 pages doi:10.1155/2012/252676 Review Article Review of NVP and HG and Early Pharmacotherapeutic Intervention Shannon M. Clark, Maged M. Costantine, and Gary D. V. Hankins Division of MFM, Department of Obstetrics and Gynecology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USA Correspondence should be addressed to Shannon M. Clark, shclark@ Received 30 August 2011; Revised 15 October 2011; Accepted 15 October 2011 Academic Editor: Gideon Koren Copyright © 2012 Shannon M. Clark et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. NVP occurs in 50–90% of pregnancies, making it a common medical condition in pregnancy. Women present differently with any combination of signs and symptoms. It is appropriate to take the pregnancy-related versus nonpregnancy-related approach when determining the cause of nausea and vomiting but other causes should be considered. The most common etiologies for NVP include the hormonal changes associated with pregnancy, the physiologic changes in the gastrointestinal tract, and a genetic predisposition. Up to 10% of women will require pharmacotherapy to treat the symptoms of NVP despite conservative measures. ACOG currently recommends that a combination of oral pyridoxine hydrochloride and doxylamine succinate be used as first- line treatment for NVP if pyridoxine monotherapy does not relieve symptoms. A review of NVP and early pharmacotherapeutic management is presented due to the fact that NVP is largely undertreated,